Can We Regrow a Meibomian Gland? How?

I firmly believe we can regrow meibomian glands. 

The question is how can this be done and how quickly can we prove it and make it available to patients.

A recent study noted below shows the progress being made to regrow tissues.

There is hope.

We just need:

1. the right Cannula (please consider contacting Dr. Maskin to ask him to share/sell his Cannulas with Dr. Cremers: Dry Eye And Cornea Treatment Center: (813) 875-0000

and

2. The right "Growth Cocktail." I think I  have the right receipe. We have inserted each growth factor (autologous PRP, autologous adipose-derived stem cells, and Cord Blood Serum) separately into patients' meibomian glands without any side effects and some benefit.

3. Funds: we have a patient who is helping us raise $1 million to move this project forward: if you would like to be donate to our research, please contact Michelle: MSoto@voeyedr.com

4. We have the IRB approval. 

It can be done. It is a matter of time and funds. 

SLC

https://wyss.harvard.edu/news/achieving-a-milestone-scientists-regrow-frogs-lost-leg/?utm_source=SilverpopMailing&utm_medium=email&utm_campaign=Daily%20Gazette%2020220128%20(1)&spMailingID=34077439&spUserID=MjM3NjI4OTIwMDAyS0&spJobID=2104338506&spReportId=MjEwNDMzODUwNgS2

Achieving a milestone, scientists regrow frog’s lost leg

January 26, 2022

• Facebook
 
• Twitter
 
• Linked in

Frogs briefly treated with a five-drug cocktail administered by a wearable bioreactor were able to regrow a functional, nearly complete limb

By Mike Silver / Tufts University

(MEDFORD, Mass.) – For millions of patients who have lost limbs for reasons ranging from diabetes to trauma, the possibility of regaining function through natural regeneration remains out of reach. Regrowth of legs and arms remains the province of salamanders and superheroes. But in a study published in the journal Science Advances, scientists at the Wyss Institute at Harvard University and Tufts University have brought us a step closer to the goal of regenerative medicine. On adult frogs, which are naturally unable to regenerate limbs, the researchers were able to trigger regrowth of a lost leg using a five-drug cocktail applied for just 24 hours in a silicone wearable bioreactor dome (BioDome) that seals in the elixir over the stump. That brief treatment sets in motion an 18-month period of regrowth that restores a functional leg.

Many creatures have the capability of full regeneration of at least some limbs, including salamanders, starfish, crabs, and lizards. Flatworms can even be cut up into pieces, with each piece reconstructing an entire organism. As humans, we have lost much of that capability, but not entirely. We are capable of closing wounds with new tissue growth, and our livers have a remarkable, almost flatworm-like capability of regenerating to full size after a 50% loss. But loss of a large and structurally complex limb – an arm or leg – cannot be restored by any natural process of regeneration in humans or mammals. In fact, we tend to cover major injuries with an amorphous mass of scar tissue, protecting it from further blood loss and infection and preventing regenerative growth.

Kickstarting regeneration

The BioDome, shown here, is an innovative device that concentrates a five-drug cocktail around the stump of a frog’s missing limb and successfully promotes regeneration of bone and soft tissues. Credit: Tufts University

The Tufts researchers triggered the regenerative process in African clawed frogs by enclosing the wound in a silicone cap, which they call a BioDome, containing a silk protein gel loaded with the five-drug cocktail. Each drug fulfilled a different purpose, including tamping down inflammation, inhibiting the production of collagen which would lead to scarring, and encouraging the new growth of nerve fibers, blood vessels, and muscle. The combination and the bioreactor provided a local environment and signals that tipped the scales away from the natural tendency to close off the stump, and toward the regenerative process.

The researchers observed dramatic growth of tissue in many of the treated frogs, re-creating an almost fully functional leg. The new limbs had bone structure extended with features similar to a natural limb’s bone structure, a richer complement of internal tissues (including neurons), and several “toes” grew from the end of the limb, although without the support of underlying bone. The regrown limb moved and responded to stimuli such as a touch from a stiff fiber, and the frogs were able to make use of it for swimming through water, moving much like a normal frog would.

“It’s exciting to see that the drugs we selected were helping to create an almost complete limb,” said Nirosha Murugan, Ph.D., a former research affiliate at the Allen Discovery Center at Tufts and first author of the paper. “The fact that it required only a brief exposure to the drugs to set in motion a months-long regeneration process suggests that frogs and perhaps other animals may have dormant regenerative capabilities that can be triggered into action.” Murugan is now an Assistant Professor at Algoma University in Ontario, Canada.

The researchers explored the mechanisms by which the brief intervention could lead to long-term growth. Within the first few days after treatment, they detected the activation of known molecular pathways that are normally used in a developing embryo to help the body take shape. Activation of these pathways could allow the burden of growth and organization of tissue to be handled by the limb itself, similar to how it occurs in an embryo, rather than require ongoing therapeutic intervention over the many months it takes to grow the limb.

“Mammals and other regenerating animals will usually have their injuries exposed to air or making contact with the ground, and they can take days to weeks to close up with scar tissue,” said David Kaplan, Ph.D., Stern Family Professor of Engineering at Tufts and co-author of the study. “Using the BioDome cap in the first 24 hours helps mimic an amniotic-like environment which, along with the right drugs, allows the rebuilding process to proceed without the interference of scar tissue.”

Next steps in frogs and mammals

Researchers coaxed an African clawed frog (Xenopus laevis, seen here) to regenerate a lost limb, even though adult frogs do not naturally have this ability. Credit: Shutterstock/ Dewald Kirsten

Previous work by the Tufts team showed a significant degree of limb growth triggered by a single drug, progesterone, applied with the BioDome. However, the resulting limb grew as a spike and was far from the more normally shaped, functional limb achieved in the current study. The five-drug cocktail represents a significant milestone toward the restoration of fully functional limbs and suggests further exploration of drug and growth factor combinations could lead to regrown limbs that are even more functionally complete, with normal digits, webbing, and more detailed skeletal and muscular features.

“We’ll be testing how this treatment could apply to mammals next,” said corresponding author Michael Levin, Ph.D., who is an Associate Faculty member of the Wyss Institute as well as the Vannevar Bush Professor of Biology at Tufts University’s School of Arts & Sciences and Director of the Allen Discovery Center at Tufts. “Covering the open wound with a liquid environment under the BioDome, with the right drug cocktail, could provide the necessary first signals to set the regenerative process in motion. It’s a strategy focused on triggering dormant, inherent anatomical patterning programs, not micromanaging complex growth, since adult animals still have the information needed to make their body structures.”

Additional authors of the paper include Hannah Vigran, Kelsie Miller, and Cody Rasmussen-Ivey from the Allen Discovery Center and Tufts University; Annie Golding and Quang L. Pham from Tufts University; Megan Sperry from Tufts University and the Wyss Institute; and Anna Kane from the Allen Discovery Center, Tufts University, and the Wyss Institute.

This research was supported by the Allen Discovery Center program through The Paul G. Allen Frontiers Group (12171), as well as grants from NIH (R01 AR005593, R01 AR061988 and P41EB027062) and the W.M. Keck Foundation (5903).